Dinical and immunological status of patients with chronic hepatitis С on the background of comorbidity
- Authors: Basina V.V.1, Dzemova A.A.1,2, Arsent'eva N.A.2, Novak K.E.1, Esaulenko E.V.1,2, Totolyan A.A.2
-
Affiliations:
- Saint Petersburg State Pediatric Medical University
- Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology
- Issue: Vol 23, No 5 (2021)
- Pages: 428-433
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/95489
- DOI: https://doi.org/10.26442/20751753.2021.5.200909
- ID: 95489
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Valentina V. Basina
Saint Petersburg State Pediatric Medical University
Email: v.basina@mail.ru
канд. мед. наук, ассистент каф. Saint Petersburg, Russia
Aleksandra A. Dzemova
Saint Petersburg State Pediatric Medical University; Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiologyассистент каф. Saint Petersburg, Russia
Natalya A. Arsent'eva
Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiologyканд. биол. наук, ст. науч. сотр. лаб. Saint Petersburg, Russia
Kseniya E. Novak
Saint Petersburg State Pediatric Medical Universityканд. мед. наук, доц. каф. Saint Petersburg, Russia
Elena V. Esaulenko
Saint Petersburg State Pediatric Medical University; Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiologyд-р мед. наук, проф., зав. каф. Saint Petersburg, Russia
Areg A. Totolyan
Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiologyакад. РАН, д-р мед. наук, проф., зав. лаб. Saint Petersburg, Russia
References
- European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199-236.
- Эсауленко Е.В., Новак К.Е., Басина В.В., и др. Распространенность коморбидности при хроническом вирусном гепатите С. Мед. алфавит. 2021;1:66-70
- Heydtmann M, Adams DH. Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology. 2009;49(2):676-88. doi: 10.1002/hep.22763
- Арсентьева Н.А., Семенов А.В., Любимова Н.Е., и др. Содержание цитокинов и хемокинов в плазме крови больных хроническим вирусным гепатитом С. Рос. иммунологический журн. 2015;9(18):83-92
- Арсентьева Н.А., Семенов А.В., Любимова Н.Е., и др. Хемокиновые рецепторы CXCR3 и CCR6 и их лиганды в печени и крови больных хроническим вирусным гепатитом C. Бюл. эксперим. биологии и медицины. 2015;160(8):218-22
- Larrubia J, Benito-Martinez S, Calvino M, et al. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol. 2008;14(47):7149-59. doi: 10.3748/wjg.14.7149
- Cooper C, Galanakis C, Donelle J, et al. HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study. BMC Infect Dis. 2019;19:712. doi: 10.1186/s12879-019-4315-6
- Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol. 2014;61(1):69-78. doi: 10.1016/j.jhep.2014.08.003
- Новак К.Е. Клинико-морфологическая характеристика субкомпенсированного и декомпенсированного цирроза печени вирусной этиологии. Педиатр. 2011;2(2):47-52
- Эсауленко Е.В., Сухорук А.А. Трансплантация в детском возрасте и у взрослых. Педиатр. 2015;6(3):98-103
- Kuna L, Jakab J, Smolic R, et al. HCV Extra hepatic manifestations. J Clin Trans Hepatol. 2019;7(2):172-82. doi: 10.14218/JCTH.2018.00049
- Labenz С, Huber Y, Kalliga E, et al. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Aliment Pharmacol Ther. 2018;48(10):1109-16. doi: 10.1111/apt.14976
- McPherson S, Gosrani S, Hogg S, et al. Increased cardiovascular risk and reduced quality of life are highly prevalent among individuals with hepatitis C. BMJ Open Gastroenterol. 2020;7(1):000470. D0I:10.1136/bmjgast-2020-000470
- Gonnella D. Type 1 diabetes and MIG. Clin Ther. 2019;170(6):465-71. doi: 10.7417/CT.2019.2177
- Antonelli А, Ferrari S, Corrado A, et al. CXCR3, CXCL10 and type 1 diabetes. Cytokine Growth Factor Rev. 2014;25(1):57-65. doi: 10.1016/j.cytogfr.2014.01.006
- Corrado A, Ferrari S, Ferri C, et al. Type 1 diabetes and (C-X-C motif) ligand (CXCL) 10 chemokine. Clin Ther. 2014;165(2):181-5. doi: 10.7471/CT.2014.1706
- Ferrari S, Ruffilli I, Colaci M, et al. CXCL10 in psoriasis. Adv Med Sci. 2015;60(2):349-54. doi: 10.1016/j.advms.2015.07.011
- Antonelli A, Ferrari S, Giuggioli D, et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev. 2014;13(3):272-80. doi: 10.1016/j.autrev.2013.10.010
- Sayed-Ahmed L, Kotb N, El-Serogy H, et al. TNF-alpha and CXCL-10 correlation with insulin resistance in patients with chronic hepatitis C virus infection. Egypt J Immunol. 2010;17(1):101-11
- Hung C-H, Lee C-M, Lu S-N. Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. Expert Rev Anti Infect Ther. 2011;9(5):525-33. doi: 10.1586/eri.11.33
- Liu C, Feng X, Li Q, et al. TNF-a and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis. Cytokine. 2016;86:100-9. doi: 10.1016/j.cyto.2016.06.028